Exposure to Remicade (Infliximab) During Pregnancy in Patients With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: a Review and Analysis of Birth Outcomes From the Swedish and Danish Medical Birth Registers.

Trial Profile

Exposure to Remicade (Infliximab) During Pregnancy in Patients With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: a Review and Analysis of Birth Outcomes From the Swedish and Danish Medical Birth Registers.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Inflammatory bowel diseases; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Centocor; Janssen Biotech
  • Most Recent Events

    • 01 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 08 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 08 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top